Home » Stocks » SAVA

Cassava Sciences, Inc. (SAVA)

Stock Price: $43.41 USD -1.07 (-2.41%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $44.30 +0.89 (2.05%) Mar 5, 7:59 PM
Market Cap 1.69B
Revenue (ttm) n/a
Net Income (ttm) -5.23M
Shares Out 24.97M
EPS (ttm) -0.23
PE Ratio n/a
Forward PE 34.01
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $43.41
Previous Close $44.48
Change ($) -1.07
Change (%) -2.41%
Day's Open 45.26
Day's Range 35.62 - 45.46
Day's Volume 4,066,974
52-Week Range 1.63 - 117.54

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 12 hours ago

Its promising potential treatment for Alzheimer's disease is going to enter phase 3 trials later this year.

InvestorPlace - 2 days ago

SAVA stock has plenty of long-term potential after the company posted clinical results from its Alzheimer's disease study. The post Why Cassava Sciences Has Tremendous Upside Potential appeare...

InvestorPlace - 3 days ago

Cassava Sciences will likely be a winner in the fight against Alzheimer's. If successful, SAVA stock is worth significantly more.

Zacks Investment Research - 1 week ago

Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.

Zacks Investment Research - 1 week ago

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $52.37, moving -1.23% from the previous trading session.

Zacks Investment Research - 1 week ago

Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 results.

GlobeNewsWire - 1 week ago

AUSTIN, Texas, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, has been i...

Benzinga - 1 week ago

Cassava Sciences Inc (NASDAQ: SAVA) completes an End-of-Phase 2 (EOP2) meeting with the FDA for its lead candidate, simufilam, in Alzheimer's disease. The FDA and Cassava Sciences agree on key...

GlobeNewsWire - 1 week ago

- Two Upcoming Phase 3 Studies and a Previously Completed Phase 2 Program  Support a New Drug Application Filing for Simufilam in Alzheimer's disease -

Zacks Investment Research - 2 weeks ago

Is (SAVA) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 2 weeks ago

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $51.22, moving -1.18% from the previous trading session.

The Motley Fool - 3 weeks ago

These momentum stocks have been printing money for retail investors in recent weeks.

Other stocks mentioned: KOSS, NAKD, SNDL, TLRY
GlobeNewsWire - 3 weeks ago

AUSTIN, Texas, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer's dise...

The Motley Fool - 3 weeks ago

This company's experimental Alzheimer's disease drug looks very promising, but there are a few key caveats.

The Motley Fool - 3 weeks ago

Many are following these two stocks, which took hits on Wednesday.

Other stocks mentioned: OCGN
Benzinga - 3 weeks ago

Cassava Sciences Inc (NASDAQ: SAVA) has entered into a definitive agreement with several institutional investors for the purchase of 4.1 million common shares at $49 per share, for gross proce...

GlobeNewsWire - 3 weeks ago

AUSTIN, Texas, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer's dise...

Zacks Investment Research - 3 weeks ago

Cassava (SAVA) provides outline for future study plans on its Alzheimer's disease candidate, simufilam.

The Motley Fool - 3 weeks ago

Can this company's Alzheimer's disease candidate deliver further gains ahead?

The Motley Fool - 3 weeks ago

Find out what these two red-hot stocks are doing to earn investors' love.

Other stocks mentioned: OCGN
Benzinga - 3 weeks ago

Cassava Sciences Inc (NASDAQ: SAVA) shares were trading solidly higher Monday on above-average volume in reaction to updates from the company on clinical programs and upcoming catalysts. The A...

GlobeNewsWire - 3 weeks ago

AUSTIN, Texas, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer's disease, today anno...

Benzinga - 1 month ago

Of the stocks with volatile price action this week, perhaps the wildest has been Cassava Science Inc. (NASDAQ: SAVA) — the PreMarket Prep Stock of the Day. The Company: Cassava Sciences Inc is...

Investors Business Daily - 1 month ago

Cassava Sciences said Thursday its Alzheimer's treatment showed promise in a six-month study and SAVA stock bolted to a record high. The study is still enrolling patients.

The Motley Fool - 1 month ago

Investors are betting this underdog will succeed where even the most reputable of biotech firms have failed.

Other stocks mentioned: BIIB, LLY, MRK, PFE
Benzinga - 1 month ago

Cassava Sciences Inc (NASDAQ: SAVA) shares rallied over 97% today in the regular and after-hours sessions. What Happened: The upwards movement was an extension from a day ago when shares rose ...

Zacks Investment Research - 1 month ago

From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.

Other stocks mentioned: AVXL, AXSM, HOLX, MRNA, NVAX, VIVO, VXRT
InvestorPlace - 1 month ago

Cassava Sciences (SAVA) stock is on the rise Wednesday after revealing interim results from a recent Alzheimer's disease clinical trial. The post SAVA Stock: 12 Things for Investors to Know Ab...

Zacks Investment Research - 1 month ago

Cassava's (SAVA) Alzheimer's disease candidate, simufilam, improved cognition and behavior scores following six months of treatment in an open-label clinical study.

The Motley Fool - 1 month ago

The biotech's experimental Alzheimer's treatment could be a game changer.

Benzinga - 1 month ago

Cassava Sciences (NASDAQ: SAVA) shares are trading higher Tuesday after the company announced results of an interim analysis from an open-label study of simufilam, its lead drug candidate for ...

Business Insider - 1 month ago

Shares of Cassava Sciences soared as much as 221% Tuesday after the biopharmaceutical company announced upbeat data on its leading drug candidate for the treatment of Alzheimer's disease. The ...

Market Watch - 1 month ago

Shares of Cassava Sciences Inc. more than doubled toward a near 10-year high in very active trading Tuesday, after the company focused on neurodegenerative disease treatments announced upbeat ...

Seeking Alpha - 1 month ago

Interim analysis of the first 50 patients to complete 6 months of sumifilam treatment came sooner than we expected. The results are nothing short of phenomenal and historic - "Patients' cognit...

Seeking Alpha - 1 month ago

It's been 20 days since we released a report on Cassava Sciences saying it could be the best-performing stock of 2021. The stock has already doubled, but we think this is just the beginning.

The Motley Fool - 1 month ago

These three healthcare stocks all had a good year in 2020, and their businesses look to have plenty of growth again in 2021.

Other stocks mentioned: IDXX, PHG
Seeking Alpha - 1 month ago

Treating The Causes Of Alzheimer's Disease: The Case For Anavex 2-73

Other stocks mentioned: AVXL, BHVN, BIIB, LLY
GlobeNewsWire - 2 months ago

Dr. Kupiec will leverage three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy to lead the Company's Phase 3 development of simufilam for Alzheimer's disease. Dr. Kupie...

Zacks Investment Research - 2 months ago

As of late, it has definitely been a great time to be an investor in Cassava Sciences (SAVA).

GlobeNewsWire - 3 months ago

Future References to Lead Drug Candidate for Alzheimer's Disease Will Be Simufilam Future References to Lead Drug Candidate for Alzheimer's Disease Will Be Simufilam

The Motley Fool - 3 months ago

While most investors are watching the companies working to end the COVID-19 crisis, take a moment to consider three that are continuing the fight against an even more stubborn disease.

Other stocks mentioned: DNLI, RHHBY
GlobeNewsWire - 3 months ago

AUSTIN, Texas, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer's dise...

The Motley Fool - 3 months ago

A public offering is weighing on the biophama's shares today.

GlobeNewsWire - 3 months ago

AUSTIN, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer's dise...

The Motley Fool - 3 months ago

This biotech titan should be a top player on the merger and acquisition scene next year.

Other stocks mentioned: BIIB, AUPH, HRTX
GlobeNewsWire - 3 months ago

AUSTIN, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today reported financial results ...

InvestorPlace - 4 months ago

Cassava Sciences (SAVA) is in the news Wednesday after announcing data from a recent clinical trial concerning Alzheimer's disease. The post Cassava Sciences News: Why SAVA Stock Is Soaring 24...

GlobeNewsWire - 4 months ago

Alzheimer's Patients Treated with Sumifilam Show ed a Statistically Significant (p

Zacks Investment Research - 4 months ago

Investors will be keen on updates from the recent study on its lead candidate, sumifilam, when Cassava (SAVA) reports Q3 results.

The Motley Fool - 4 months ago

A positive note from an investment bank about the biotech caught investors' attention.

About SAVA

Cassava Sciences, a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.

Industry
Biotechnology
Founded
1998
CEO
Remi Barbier
Employees
9
Stock Exchange
NASDAQ
Ticker Symbol
SAVA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for SAVA stock is "Buy." The 12-month stock price forecast is 67.00, which is an increase of 54.34% from the latest price.

Price Target
$67.00
(54.34% upside)
Analyst Consensus: Buy